Evidence map›Paper›PMID 32635622›Full record

ArticleMolecules (Basel, Switzerland)2020

Curcumin-1,2,3-Triazole Conjugation for Targeting the Cancer Apoptosis Machinery.

Francesca Seghetti, Rita Maria Concetta Di Martino, Elena Catanzaro, Alessandra Bisi, Silvia Gobbi, Angela Rampa, Barbara Canonico, Mariele Montanari, Dmitri V Krysko, Stefano Papa and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Francesca SeghettiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0003-0478-7341
Rita Maria Concetta Di MartinoDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0003-2287-3331
Elena CatanzaroDepartment for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.ORCID 0000-0001-7699-3414
Alessandra BisiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0003-4662-4743
Silvia GobbiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0001-9044-5377
Angela RampaDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0002-8028-8758
Barbara CanonicoDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Via Ca' Le Suore, 2, 61029 Urbino, Italy.ORCID 0000-0003-3383-715X
Mariele MontanariDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Via Ca' Le Suore, 2, 61029 Urbino, Italy.
Dmitri V KryskoCell Death Investigation and Therapy Laboratory, Department of Human Structure and Repair, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-9692-2047
Stefano PapaDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Via Ca' Le Suore, 2, 61029 Urbino, Italy.ORCID 0000-0001-9291-0527
Carmela FimognariDepartment for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.ORCID 0000-0002-2461-8214
Federica BellutiDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0002-6365-5579
University of Bologna · ITUniversity of Urbino · ITSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burden of neoplastic diseases is widely recognized as a severe cause of mortality. The clinical inadequacy of most anticancer therapeutics urgently prompted intense drug discovery efforts toward the identification of new chemical entities endowed with a potent and safe antitumor profile. In this scenario, targeting cancer cells apoptosis machinery has emerged as a relevant strategy, useful for tackling the emergence of drug resistance. On this basis, a small library of naturally inspired hybrid molecules was obtained by combining, through a click chemistry approach, "privileged" synthons such as curcumin scaffold and 1,2,3-triazole building block. Compound

Indexed as

ApoptosisAntineoplastic AgentsCell ProliferationCurcuminDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansLeukemia, T-CellMembrane Potential, MitochondrialMolecular StructurePrecursor Cell Lymphoblastic Leukemia-LymphomaStructure-Activity RelationshipTriazolesTumor Cells, CulturedAntineoplastic AgentsCurcuminTriazolesapoptosiscell cyclecell deathclick chemistrycurcuminflow cytometryfluorineprivileged structuretriazole

Identifiers

PMID32635622
PMCPMC7412087
OpenAlexW3038710590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.